BioInvent International
Sweden - Lund
BiotechnologyFocus: Antibody Drugs
BioInvent International is a life sciences company focused on Antibody Drugs.
OncologyCardiovascular
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
HealthyClinical Trials (1)
NCT00612417Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402
Phase 1MLDL1278A
HealthyClinical Trials (1)
NCT01486823Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects
Phase 1TB-403
Solid TumorsClinical Trials (1)
NCT00702494Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Phase 1TB-402
HealthyClinical Trials (1)
NCT00612196A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
Phase 1BI-505
Multiple MyelomaClinical Trials (1)
NCT01025206A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
Phase 1LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
HealthyClinical Trials (1)
NCT00618579Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Phase 1pembrolizumab
Melanoma MetastaticClinical Trials (1)
NCT06784648Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Phase 1/2BI-1910
Solid TumorsClinical Trials (1)
NCT06205706BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Phase 1/2BI-1808
Advanced MalignanciesClinical Trials (1)
NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/2BT-001
Metastatic CancerClinical Trials (1)
NCT04725331A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2BI1206
Solid Tumor, AdultClinical Trials (1)
NCT04219254A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2BI-1206 single agent dose escalation phase
B-cell LymphomaClinical Trials (1)
NCT02933320BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Phase 1/2BI-1607
HER2-positive Breast CancerClinical Trials (1)
NCT05555251BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT03571568A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/2BI-505
Multiple MyelomaClinical Trials (1)
NCT02756728A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
Phase 1/2Phase 2
Clinical Trials (1)
NCT00793234Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
Phase 2MLDL1278A
AtherosclerosisClinical Trials (1)
NCT01258907A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Phase 2Phase 2
Clinical Trials (1)
NCT01344954Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
Phase 2Phase 2
Clinical Trials (1)
NCT01838369A Phase II Study of BI-505 in Smoldering Multiple Myeloma
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 1988
Portfolio: 19 clinical trials
Top TAs: Oncology, Cardiovascular
Publications: 25 in PubMed
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles